Sofituzumab vedotin (solution) (Synonyms: DMUC5754A (solution))

Cat. No.: HY-P99593A: FAQs
Data Sheet

Molarity Calculator

Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker.

For research use only. We do not sell to patients.

Sofituzumab vedotin (solution) Chemical Structure

CAS No. : 1418200-58-4

Size		Stock
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Sofituzumab vedotin (solution):

Other Forms of Sofituzumab vedotin (solution):

Sofituzumab vedotin In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000 ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	OVCAR-3 and PC3/MUC16TMlong cells
Concentration:	0.1-10000 ng/mL
Incubation Time:	3 days for OVCAR-3 and 5 days for PC3/MUC16TMlong
Result:	Significantly inhibited cell proliferation above 100 ng/mL.

In Vivo

Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts^[3].
Dosage:	2.8 mg/kg
Administration:	IV, once weekly for 4 total doses
Result:	Improved survival.

CAS No.

1418200-58-4

SMILES

[Sofituzumab vedotin (solution)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223. [Content Brief]

[2]. Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. [Content Brief]

[3]. Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32. [Content Brief]

Sofituzumab vedotin (solution) Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sofituzumab vedotin (solution)1418200-58-4DMUC5754A (solution)Antibody-Drug Conjugates (ADCs)Antibody-Drug Conjugatesovarian cancerpancreatic cancerOVCAR-3PC3/MUC16TMlongInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks